ArticlePloS one2010
Convergence of Rad6/Rad18 and Fanconi anemia tumor suppressor pathways upon DNA damage.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Role of Rad18 in B cell activation and lymphomagenesis.Scientific reports · 2024Article
- Focal Point of Fanconi Anemia Signaling.International journal of molecular sciences · 2021Review
- A new look at molecular biology of breast cancer.Cancer biology & therapy · 2019Review
- Fanconi Anemia Signaling and Cancer.Trends in cancer · 2017Review
- Article
- FANCD2 and DNA Damage.International journal of molecular sciences · 2017Review
- Article
- Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.Biochemical and biophysical research communications · 2016Article
- Chromosomal Integrity after UV Irradiation Requires FANCD2-Mediated Repair of Double Strand Breaks.PLoS genetics · 2016Article
- CRISPR-Cas9-based target validation for p53-reactivating model compounds.Nature chemical biology · 2016Article
- Mutated Fanconi anemia pathway in non-Fanconi anemia cancers.Oncotarget · 2015Article
- The Fanconi Anemia DNA Repair Pathway Is Regulated by an Interaction between Ubiquitin and the E2-like Fold Domain of FANCL.The Journal of biological chemistry · 2015Article
- Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate.Oncotarget · 2014Article
- The Fanconi anemia ID2 complex: dueling saxes at the crossroads.Cell cycle (Georgetown, Tex.) · 2014Review
- Advances in the understanding of the Fanconi anemia tumor suppressor pathway.Cancer biology & therapy · 2013Review
- In vitro FANCD2 monoubiquitination by HHR6 and hRad18.Cell cycle (Georgetown, Tex.) · 2013Article
- A hidden role of the inactivated FANCD2: upregulating ΔNp63.Oncotarget · 2013Article
- Readers of PCNA modifications.Chromosoma · 2013Review
- Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA damage.Cell cycle (Georgetown, Tex.) · 2013Article
- FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.Cell cycle (Georgetown, Tex.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Extremely high cancer incidence associated with patients with Fanconi anemia (FA) suggests the importance of the FA signaling pathway in the suppression of non-FA human tumor development. Indeed, we found that an impaired FA signaling pathway substantially contributes to the development of non-FA human tumors. However, the mechanisms underlying the function of the FA pathway remain less understood. Using RNA interfering approach in combining with cell proliferation and reporter assays, we showed that the function of FA signaling pathway is at least partly mediated through coupling with hRad6/hRad18 signaling (HHR6 pathway). We previously reported that FANCD2 monoubiquitination, a hallmark of the FA pathway activation, can be regulated by HHR6. Here we found that hRad18 can also regulate activation of the FA pathway. More importantly, we found that FANCD2 is capable of modulating activity of DNA translesion synthesis polymerase eta, an effector of HHR6 pathway. These results provide novel insights into how the FA pathway is intertwined with HHR6 pathway to maintain chromosomal stability and suppress the development of human cancer, representing an important conceptual advance in the field of FA cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.